Journal of Medicinal Chemistry · 2020 · 42 citations · 29 references
PharmacyMedicinal ChemistryPharmacologyCancer PharmacologyDrug DesignDrug DiscoveryEnzyme InhibitionHit-to-lead OptimizationLead Compound DesignLead DiscoveryLigand-based DesignPotency OptimizationBioactivityBioactivity AssessmentChemical Synthesis Of AnaloguesInhibitor SpecificityLate-stage Functionalization Via Cross-couplingMedicinal Chemistry ApplicationsPyridine ChemistryPyridine Synthesis
SIS3 is a specific inhibitor of Smad3 that inhibits the TGFβ1-induced phosphorylation of Smad3. In this article, a variety of SIS3 derivatives were designed and synthesized to discover potential inhibitors against P-glycoprotein-mediated multidrug resistance aided by late-stage functionalization of a 2-(4-(pyridin-2-yl)phenoxy)pyridine analogue. A novel class of potent P-gp reversal agents were investigated, and a lead compound 37 was identified as a potent P-gp reversal agent with strong bioactivity and outstanding affinity for P-gp.
29
Monitoring Drug Target Engagement in Cells and Tissues Using the Cellular Thermal Shift Assay
Daniel Martinez Molina, Rozbeh Jafari, Marina Ignatushchenko et al. · Science · 2013 · 2.2K citations
Medicine, Oncology, Pharmacology +17
Mechanisms of Multidrug Resistance in Cancer
Jean‐Pierre Gillet, Michael M. Gottesman · Methods in molecular biology · 2009 · 687 citations
Medicine, Oncology, Pharmacology +12